Göteborgs Universitet Sahlgrenska Center for Cancer Research

The Göteborgs Universitet Sahlgrenska Center for Cancer Research is conducting research on ER‑positive/HER2‑negative breast cancer in the neoadjuvant setting, aiming to assess how adding the investigational agent PF‑07220060 to standard letrozole influences tumor proliferation.

• Evaluation of Ki‑67 as an early marker of treatment response
• Comparison of combination therapy versus letrozole alone
• Insights into hormone‑driven tumor biology

Findings may guide future treatment strategies for postmenopausal patients with hormone‑responsive disease.

A separate trial at the same site explores short‑term hormone blockade in premenopausal women with ER‑positive/HER2‑negative early breast cancer, testing the novel oral selective estrogen receptor degrader giredestrant with and without the GnRH agonist triptorelin.

• Assessment of anti‑proliferative activity versus standard anastrozole
• Investigation of the added benefit of triptorelin to giredestrant
• Potential for non‑invasive biomarkers to predict response

Results could expand therapeutic options for younger patients undergoing surgery.